Barriers to innovation - WHO archives

See also Figure 8.3.2 which provides supporting data showing the inverse relationship between rising pharmaceutical R&D spending and FDA . approvals. for new molecular entities. To be sure, Figure 3 connects two very different timelines. The number of NCEs approved by the FDA is occurring at least a decade after initial investment in R&D. ................
................